EyeCool Therapeutics, Inc. is looking forward to participating in BTIG’s 5th Annual Ophthalmology Day on Monday, December 1, 2025 from 2:30-2:55 PM ET, where leaders across the field will explore emerging innovation in ophthalmology.
Our Chief Executive Officer, Ruben F. Salinas, Ph.D., will present how our non-invasive cold therapy technology is redefining comfort and care for patients with chronic ocular surface pain (COSP) with a simple 4 minute in-clinic procedure.
The presentation will include details on our most recent 12-month longitudinal study assessing eyes treated with the ETX-4143 System in EyeCool’s RCT pilot, as well as preliminary findings from the company’s observational study using in vivo confocal microscopy to characterize the impact of the ETX-4143 System on corneal micro-anatomy and ocular surface inflammatory markers.
This event is hosted by BTIG, a global financial services firm specializing in institutional trading, investment banking, research, and related brokerage services. BTIG’s Corporate Access program convenes sector focused events across healthcare, technology, digital assets, consumer, energy and infrastructure, financials, industrials, and real estate.
To join the conference, please contact corporateaccess@btig.com
Warning: This product has not been approved or cleared for marketing by the U.S. Food and Drug Administration and is considered an investigational device.
Thank you for your continued interest in EyeCool Therapeutics. We look forward to engaging with you at the event.
EyeCool Therapeutics, Inc.